BioCentury
ARTICLE | Clinical News

Dolizem diltiazem cream: Development discontinued

August 18, 2014 7:00 AM UTC

Assembly said it will not pursue further development of VEN 307 and ended a March 2007 deal with S.L.A. Pharma granting Assembly exclusive, North American rights to the product for the topical treatment of anal fissures. The company said it discontinued development as a result of the FDA feedback in June on an NDA for the topical formulation of diltiazem and a post-merger focus on Assembly’s therapeutics for HBV infection and Clostridium difficile-associated diarrhea (CDAD) infection (see BioCentury, July 28). ...